<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397447</url>
  </required_header>
  <id_info>
    <org_study_id>MCHDM2</org_study_id>
    <nct_id>NCT02397447</nct_id>
  </id_info>
  <brief_title>Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion</brief_title>
  <official_title>Effect of Momordica Charantia Administration on Insulin Sensitivity and Insulin Secretion in Patients With Type 2 Diabetes Mellitus, Without Pharmacological Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypoglycemic effect of Momordica Charantia has been evaluated in clinical trials in
      patients with type 2 diabetes mellitus. Important reductions in fasting plasma glucose,
      glycated hemoglobin (A1C), and fructosamine were observed. It is unknown whether this
      improvement is due to an improvement in insulin sensitivity and insulin secretion. The
      purpose of this study is to evaluate the effect of the administration of Momordica Charantia
      on insulin sensitivity and insulin secretion in patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo controlled clinical trial is carried out in 24 patients
      with diagnosis of diabetes mellitus type 2 according to the criteria of the American Diabetes
      Association. Patients are assigned to two different arms: one group receives Momordica
      Charantia, 2 capsules with 500 mg twice daily before breakfast and dinner for 90 days or
      placebo, under the same scheme of treatment.

      An oral glucose tolerance test is performed before and after the intervention. Matsuda index,
      Stumvoll index and Insulinogenic index are calculated to assess insulin sensitivity and
      insulin secretion.

      Other clinical and laboratory parameters that are evaluated include: Body weight, body mass
      index, waist circumference, blood pressure, body fat percentage, fasting plasma glucose, A1C,
      creatinine, lipid profile and liver transaminases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total and First Phase of Insulin Secretion (Insulinogenic index and Stumvoll index)</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention with Insulinogenic index and Stumvoll index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity (Matsuda index)</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention with Matsuda index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose (spectrophotometry)</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A1C</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by high-performance liquid chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High density lipoprotein cholesterol</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very low density lipoprotein</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention by spectrophotometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>90 days</time_frame>
    <description>Before and after intervention using a baumanometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Momordica charantia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Momordica charantia</intervention_name>
    <description>Momordica Charantia: 2000 mg per day for three months</description>
    <arm_group_label>Momordica charantia</arm_group_label>
    <other_name>Bitter gourd, karela, balsam-pear</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 2000 mg per day for three months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcined magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of diabetes mellitus type 2 according to the criteria of the American
             Diabetes Association (&lt;5 years), without pharmacological treatment (oral antidiabetic
             drugs or insulin) at least for three months before entering the study

          -  Fasting glucose: &lt;210 mg/dl

          -  A1C: 7-9%

          -  Body mass index: 25-34.9 kg/m2

          -  Body weight without variations above or under 5% in the last three months before
             entering the study

          -  Women in childbearing years must have a contraceptive method

          -  Letter of consent and release signed by each patient

        Exclusion Criteria:

          -  Pregnant or suspected pregnant women

          -  Woman breastfeeding

          -  Medications known to affect metabolism of glucose and insulin

          -  Personal history of liver or renal disease

          -  Hypertension, thyroid or cardiovascular disease decompensated

          -  Total cholesterol &gt;= 240mg/dl, triglycerides &gt;=400mg/dl, glomerular filtration rate
             &lt;=60ml/min or liver transaminases &gt;=2.5 the upper normal limit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esperanza Martínez Abundis, PhD Science</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>January 8, 2016</last_update_submitted>
  <last_update_submitted_qc>January 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Esperanza Martínez-Abundis</investigator_full_name>
    <investigator_title>PhD. Esperanza Martínez-Abundis</investigator_title>
  </responsible_party>
  <keyword>Momordica Charantia</keyword>
  <keyword>Insulin secretion</keyword>
  <keyword>Insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Magnesium Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

